Osteoprotegerin and Myocardial Fibrosis in Patients with Aortic Stenosis by Loudon, Brodie L et al.
1SCIENTIfIC RePORtS |  (2018) 8:14550  | DOI:10.1038/s41598-018-32738-y
www.nature.com/scientificreports
Osteoprotegerin and Myocardial 
Fibrosis in Patients with Aortic 
Stenosis
Brodie L. Loudon1,2, Eleana Ntatsaki3, Simon Newsome  1, Brian Halliday1,4, Amrit Lota1,4, 
Aamir Ali1,4, Tamir Malley1, Subothini Selvendran1,4, Nikhil Aggarwal1,4, Willis Lam1, 
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Left ventricular myocardial fibrosis in patients with aortic stenosis (AS) confers worse prognosis. 
Plasma osteoprotegerin (OPG), a cytokine from the TNF receptor family, correlates with the degree 
of valve calcification in AS, reflecting the activity of the tissue RANKL/RANK/OPG (receptor activator 
of nuclear factor κΒ ligand/RANK/osteoprotegerin) axis, and is associated with poorer outcomes 
in AS. Its association with myocardial fibrosis is unknown. We hypothesised that OPG levels would 
reflect the extent of myocardial fibrosis in AS. We included 110 consecutive patients with AS who had 
undergone late-gadolinium contrast enhanced cardiovascular magnetic resonance (LGE-CMR). Patients 
were characterised according to pattern of fibrosis (no fibrosis, midwall fibrosis, or chronic myocardial 
infarction fibrosis). Serum OPG was measured with ELISA and compared between groups defined by 
valve stenosis severity. Some 36 patients had no fibrosis, 38 had midwall fibrosis, and 36 had chronic 
infarction. Patients with midwall fibrosis did not have higher levels of OPG compared to those without 
fibrosis (6.78 vs. 5.25 pmol/L, p = 0.12). There was no difference between those with midwall or chronic 
myocardial infarction fibrosis (6.78 vs. 6.97 pmol/L, p = 0.27). However, OPG levels in patients with 
chronic myocardial infarction fibrosis were significantly higher than those without fibrosis (p = 0.005).
Calcification of the cardiovascular system occurs commonly with aging. Progressive aortic valve calcification 
occurs in some patients, with symptoms presenting once critical restriction of valve-opening and left ventricular 
pressure overload ensue. The mechanisms responsible for the pathogenesis of calcific aortic stenosis (AS) are 
unknown, and likely reflect the interplay of multiple cytokine pathways and genetic factors1,2. Determining the 
ideal timing for aortic valve replacement (AVR) in AS remains a challenge. Current guideline-based indications 
for intervention depend on the severity of valve narrowing, as usually assessed with echocardiography, the pres-
ence of symptoms relating to a narrowed valve, and impairment of systolic function, as assessed by left ventricular 
ejection fraction (LVEF)3,4. Unfortunately, stenosis severity on echocardiography does not correlate well with the 
risk of progression of LV hypertrophy to heart failure, which is primarily driven by the development of myocar-
dial fibrosis5. Currently, cardiovascular magnetic resonance (CMR) remains the only non-invasive, radiation-free 
investigation enabling the visualisation of myocardial fibrosis in the late phase following gadolinium administra-
tion indicating myocardial scar6. However, the associated costs and limited access to CMR limit its routine use in 
all patients with AS. It is also recognised that patients with fibrosis have worse prognosis independently of LVEF7, 
and therefore formulating an easy, non-invasive, and cost-effective way of identifying patients with high preva-
lence of fibrosis would be clinically useful. Blood biomarkers have the potential to identify patients with fibrosis 
and lend themselves to serial monitoring of these patients. In this way, they may help to identify those patients 
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in whom greatest benefit may be gained from early AVR. Recently, the RANKL/RANK/OPG (receptor activator 
of nuclear factor κΒ ligand/RANK/osteoprotegerin) system, known to play an important role in bone turnover 
and vascular calcification8, has gained much interest in AS9. Osteoprotegerin (OPG) is a member of the tumour 
necrosis factor (TNF) receptor family and inhibits the interaction between RANKL and RANK10,11, and therefore 
may represent one such biomarker.
Most studies of tissue levels of OPG within the diseased aortic valve report a reduction in tissue OPG com-
pared to controls9,12,13, but increased mRNA levels13. In contrast, reported levels of serum OPG consistently show 
a rise in tandem with an increase in tissue RANKL/RANK activity (but not serum RANKL14), in patients with 
a range of cardiovascular conditions, including vascular calcification15–17, diabetes18, and heart failure19–21. The 
same has also been demonstrated in AS22–24. Recently, preoperative serum OPG was shown to correlate with a 
worse outcome after AVR in 124 patients with severe AS during a mean follow-up of 3.8 years23. Additionally 
in other studies22–24, OPG levels were associated with AS severity, pulmonary capillary wedge pressure, and 
NT-proBNP levels, indicating that the presence of HF may be an important determinant of serum OPG in AS. 
Interestingly, OPG levels also correlated with LV global longitudinal strain (GLS) and strain rate, but ejection 
fraction (EF) did not differ between OPG tertiles23. Subtle changes in LV longitudinal function often precede 
changes in EF25–27, and elevated OPG levels may therefore suggest underlying myocardial fibrosis, which drives 
the progression to HF5. Patients with severe AS and cardiovascular magnetic resonance (CMR)-derived meas-
ures of myocardial replacement fibrosis (either midwall or chronic myocardial infarction) have poorer out-
comes28,29. This has also been confirmed in a large prospective observational cohort study of patients with less 
severe disease30. Inflammation is known to play a critical role in the development of LV myocardial fibrosis31, 
and can also activate the RANKL/RANK/OPG system32. In an isoproterenol-induced rat model of heart fail-
ure, RANKL/RANK were shown to be crucial mediators of interleukin-17 (IL-17) induced activation of matrix 
metalloproteinase-1 (MMP-1) in cardiac fibroblasts33. In this model, treatment with both OPG and inhibitors of 
IL-17 reduced myocardial fibrosis.
The association between OPG levels and myocardial replacement fibrosis in AS remains unknown. The main 
aim of our study was to determine whether serum OPG was associated with the presence of (1) myocardial mid-
wall and (2) myocardial infarction fibrosis in patients with AS, and compare patients with mild/moderate and 
severe disease. Additionally, we investigated the prognostic role of OPG in patients with AS.
Methods
Consecutive patients with AS and late gadolinium contrast enhanced CMR (LGE-CMR) were included in 
this prospective substudy34 (ClinicalTrials.gov Identifier: NCT00930735). AS severity was assessed according 
to the most recent AHA/ACC clinical practice guidelines for management of patients with valvular heart dis-
ease3. Exclusion criteria included acute coronary syndrome, clinical suspicion or evidence of infection, dissemi-
nated malignancy, severe aortic regurgitation, more than moderate mitral regurgitation/stenosis, previous valve 
replacement, contraindication to CMR (including presence of non-conditional devices), and estimated glomeru-
lar filtration rate of <30 ml/min. This study was approved by the NHS England Research Ethics Committee, and 
was undertaken in line with the ethical standards of the Declaration of Helsinki. All patients provided written 
informed consent.
Cardiovascular Magnetic Resonance. CMR scans were performed on a 1.5 T scanner (Magnetom Sonata 
or Avanto, Siemens, Erlangen, Germany) using a standardised protocol as previously described34. In short, initial 
localiser images were used to guide acquisition of a vertical long axis (VLA) cine with balanced steady state free 
precession (SSFP) at end-expiration. This was then used to guide SSFP cines in the two-, three- and four-chamber 
views. Contiguous 10 mm short axis slices of the LV were then taken from base to apex. Retrospective ECG gating 
was preferred for the cine acquisition. In patients with arrhythmia, prospective triggering was utilised. Aortic 
valve planimetry and LV mass and volume were then calculated. After gadolinium contrast agent (Gadovist, 
Schering AG, Berlin, Germany) administration, inversion recovery-prepared spoiled gradient echo images were 
acquired in standard long- and short-axis views to detect areas of LGE28. Images were analysed offline on dedi-
cated software for LV function, volumes, mass, and AS severity (CMR Tools, Cardiovascular Imaging Solutions., 
London, United Kingdom). LV myocardial fibrosis was quantified via separate dedicated software (CVI42, Circle 
Cardiovascular Imaging, Calgary, Canada). Two independent, blinded, expert observers analysed the images with 
a third blinded observer adjudicating in cases of disagreement.
Osteoprotegerin Levels. OPG measurement from stored plasma was undertaken using monoclo-
nal anti-human OPG antibody. Detection was via biotin-labelled polyclonal anti-human OPG antibody and 
Streptavidin HRP conjugate (BioVendor, Research and Diagnostics Products). This produced a yellow colour whose 
absorbance was measured at 450 nm. A reference absorbance of 620 nm was also measured and subtracted from 
all samples before calculating concentrations. The absorbance was proportional to the concentration of OPG in 
the sample, allowing detection of OPG from 3–60 pmol/L.
Statistical analysis. Baseline data are presented as mean ± SD for continuous variables and number (pro-
portion) for categorical variables. Mann-Whitney U tests were used to test for either an association between OPG 
levels and AS severity, or OPG levels and presence (or absence) of myocardial fibrosis. Univariable and multivar-
iable linear regression analyses were performed to identify possible predictors of OPG levels. A p value of <0.05 
was taken as significant. All analyses were undertaken using Stata version 14.0 (College Station, Texas, USA).
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Results
Patient data are shown in Table 1. Mild/moderate AS was diagnosed in 35 (31.8%) patients, and severe AS in 
75 (68.2%) patients. Compared to patients with mild/moderate disease, patients with severe disease were older 
(78 ± 9 years vs 71 ± 10, p < 0.001), but well-matched in terms of gender, ethnicity, body mass index (BMI), cardi-
ovascular comorbidities and resting blood pressure. Patients with severe disease also had more severe symptoms 
by New York Heart Association (NYHA) symptom class (≥class II, 60 (81.1%) vs 19 (59.4%), p = 0.03). Drug 
therapy was very similar between groups, with the exception of calcium channel blocker therapy being more 
common in the patient group with mild/moderate disease (8/26.7%) compared to patients with severe disease 
(6/8.7%, p = 0.03). NT-proBNP levels were higher in patients with severe AS compared to those with mild/mod-
erate disease (1232 pg/ml vs. 3813 pg/ml; p = 0.002); however serum CRP levels did not differ between the groups 
(12 mg/L vs. 15 mg/L; p = 0.52). Serum creatinine was also similar between mild/moderate and severe groups 
(93 μmol/L vs 102 μmol/L, p = 0.20). The correlations between demographic, biochemical, and CMR data with 
serum OPG are presented in Table 2. Age (p < 0.0001), weight (p < 0.0001), serum creatinine (p = 0.001), diu-
retic use (p = 0.009), serum NT-proBNP (p = 0.002), CRP (p = 0.038), valve area on CMR (p = 0.011), LV mass 
(p = 0.027), and LGE % (p = 0.01) correlated with serum OPG. Baseline patient data were also well-matched 
across fibrosis-pattern groups (Supplementary Data Table 1).
CMR Data. By definition, aortic valve orifice area on CMR was significantly reduced in the severe group com-
pared to the mild/moderate group (0.7 ± 0.1 cm2 vs 1.2 ± 0.3 cm2, p < 0.00001). Ejection fraction and LV mass did 
not differ between these groups. Midwall fibrosis was detected in 11 (31.4%) patients with mild/moderate disease 
and 27 (36.0%) patients with severe disease (mild/moderate vs severe, p = 0.82). Chronic infarction pattern fibro-
sis was detected in 11 (31.4%) patients with mild/moderate disease and 25 (33.3%) patients with severe disease 
(mild/moderate vs severe, p = 0.82). Myocardial fibrosis was absent in 13 (37.1%) patients with mild/moderate 
disease and 23 (30.7%) patients with severe disease (mild/moderate vs severe, p = 0.82).
Surgical Intervention. Significantly fewer patients with mild/moderate disease underwent an intervention 
compared to patients with severe disease (14 patients vs 51 patients, 40% vs 68%, p = 0.01). Some 9/14 (64.3%) 
patients with moderate disease underwent aortic valve replacement surgery (AVR) concurrently with coronary 
artery bypass grafting (CABG) surgery for ischaemic heart disease, compared to 25/51 (49.0%) patients with 
severe disease (mild/moderate vs severe, p = 0.01).
Aortic Stenosis Severity and OPG Levels. Serum OPG levels in patients with mild/moderate disease 
were a median of 5.24 pmol/L (IQR 4.38–6.76 pmol/L). In patients with severe disease, OPG levels were a median 
of 7.43 pmol/L (IQR 4.80–9.63 pmol/L), which was significant greater than the levels in patients with mild/mod-
erate disease (p = 0.002, Fig. 1). CMR valve orifice area correlated with serum OPG levels (rs = −0.24, p = 0.011; 
Table 2). Following linear regression analysis, the severity of aortic stenosis had a significant effect on OPG levels 
(p = 0.0002). On multivariable analysis (adjusting for age, sex, presence of fibrosis, LVEF, NYHA, NT-proBNP, 
and CRP) severe AS remained significant, increasing serum OPG by 1.30 pmol/L (95% CI 0.002–2.60 pmol/L, 
p = 0.049). A further multivariable analysis was performed to exclude the effect of concomitant cardiovascular 
disease in patients with severe AS on serum OPG levels. Adjusting for CAD, diabetes, and hypertension, AS 
severity was an independent predictor of serum OPG (p = 0.008).
In order to investigate whether serum OPG levels could predict severe AS in patients, receiver operator curves 
were constructed, and the area under the ROC curve (AUC) was calculated. The AUC for AS severity was 0.69 
(Supplementary Data, Fig. 1).
Low-Gradient Aortic Stenosis. Low-gradient AS, defined as a stroke volume (SV) index <35 ml/m2, was 
identified in 16 (14.5%) patients. Of these, 3 had mild/moderate AS, and the remaining 13 had severe AS. There 
was no difference in AS severity between patients with low-gradient AS and those without (p = 0.38). CMR iden-
tified no LV fibrosis in 7 patients, midwall pattern fibrosis in 6 patients, and chronic infarction pattern fibrosis in 
3 patients. Serum OPG levels were similar between patients with low-gradient AS and those without (7.0 ± 2.9 
pmol/L vs. 7.3 ± 3.6 pmol/L; p = 0.90).
Effect of Myocardial Fibrosis on OPG Levels. LGE % on CMR correlated with serum OPG (rs = 0.25, 
p = 0.01; Table 2). The median serum OPG for patients without myocardial fibrosis on CMR (n = 36) was 5.25 
pmol/L (IQR 4.26–7.95 pmol/L). Patients with midwall fibrosis (n = 38) had a median serum OPG of 6.78 pmol/L 
(IQR 4.64–8.61 pmol/L), which was not significantly higher than those with no fibrosis (p = 0.12). Patients with a 
chronic infarction pattern of fibrosis had a median serum OPG of 6.97 pmol/L (IQR 5.43–11.12 pmol/L), which 
was significantly higher than those without fibrosis (p = 0.005) but not higher than those with midwall fibrosis 
(p = 0.27, Fig. 2). On linear regression analysis, ‘any fibrosis’ (midwall or infarction) had a significant effect on 
OPG levels (p = 0.01). On multivariable analysis (adjusting for age, sex, AS severity, & LVEF) however, a signif-
icant effect was no longer observed (p = 0.20). There was also no significant correlation between fibrosis and 
OPG levels when adjusting for CAD, diabetes, and hypertension (p = 0.11). Separating out midwall and chronic 
infarction patterns of fibrosis, linear regression analysis showed a significant effect of chronic infarction pattern 
on OPG levels (HR 2.21, 95% CI 0.57, 3.86; p = 0.009), but not of midwall fibrosis pattern (HR 1.00, 95% CI 
−0.36, 2.36; p = 0.15).
The effect of ‘any fibrosis’ on serum OPG per 1% increase in LGE on CMR was significant on univariable linear 
regression analysis (p = 0.005). On multivariable analysis, this remained significant, increasing serum OPG by 
0.16 pmol/L (95% CI 0.03–0.30 pmol/L) per 1% increase in LGE (p = 0.02, Fig. 3A). Separating out patterns of 
fibrosis on CMR, there was no significant effect of midwall fibrosis on linear regression on serum OPG (p = 0.15) 
and this remained true on multivariable analysis (p = 0.19). However, there was a significant effect of chronic 
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myocardial infarction pattern fibrosis univariable analysis (p = 0.009; Fig. 3B). On multivariable analysis, how-
ever, this effect only showed a strong trend (HR 2.11, 95% CI −0.10, 4.32; p = 0.061). Age (p = 0.004), LVEF 
(p = 0.035), and CRP (p = 0.017) each remained significant on the multivariable analysis.
Serum OPG levels predicted LV myocardial fibrosis with an AUC of 0.65 (Supplementary Data, Fig. 2).
Left Ventricular Ejection Fraction and Serum OPG Levels. LV ejection fraction did not correlate with 
serum OPG levels (rs = −0.04, p = 0.67; Table 2). CMR-derived ejection fraction was not significantly different between 
Demographics
Mild/Moderate 
(N = 35)
Severe 
(N = 75) p Value
Age, years 71 ± 10 78 ± 9 <0.001*
Male, n (%) 26 (74.3) 51 (68.0) 0.66
Hypertension, n (%) 13 (40.6) 44 (58.7) 0.096
SBP, mmHg 130 ± 19 130 ± 22 0.95
DBP, mmHg 71 ± 11 71 ± 13 0.46
Diabetes mellitus, n (%) 1 (3.8) 4 (6.1) 1.00
Current smoker, n (%) 2 (6.3) 3 (4.1) 0.64
Any coronary artery disease, n (%) 13 (37.1) 27 (36.0) 1.00
Previous stroke, n (%) 1 (2.9) 2 (2.7) 1.00
Atrial Fibrillation, n (%) 5 (14.3) 6 (8.0) 0.32
Hypercholesterolaemia, n (%) 18 (58.1) 50 (67.6) 0.38
NYHA Class ≥ II 19 (59.4) 60 (81.1) 0.03*
Caucasian 33 (94.3) 72 (96.0) 0.65
Height, cm 172 ± 12 168 ± 10 0.03*
Weight, kg 82 ± 18 75 ± 17 0.05
BMI, kg/m2 28 ± 5 26 ± 5 0.17
Pharmacotherapy
Aspirin, n (%) 19 (61.3) 44 (59.5) 1.00
Clopidogrel, n (%) 4 (13.8) 12 (16.7) 1.00
ACE-I/ARB, n (%) 13 (43.3) 38 (51.4) 0.52
Beta Blocker, n (%) 14 (46.7) 32 (44.4) 1.00
Calcium channel blocker, n (%) 8 (26.7) 6 (8.7) 0.03*
Diuretic, n (%) 14 (43.8) 43 (58.1) 0.21
Warfarin, n (%) 4 (14.3) 6 (8.3) 0.46
Amiodarone, n (%) 0 (0.0) 4 (5.6) 0.32
Statin, n (%) 20 (66.7) 54 (72.0) 0.64
Biochemical data
Osteoprotegerin, pmol/L 5.76 ± 1.96 7.91 ± 3.82 0.002*
Creatinine, μmol/L 93 ± 30 102 ± 36 0.20
NT-ProBNP (pg/mL) 1232 ± 1698 3813 ± 5489 0.002*
CRP (mg/L) 12 ± 22 15 ± 39 0.52
CMR data
CMR aortic valve area, cm2 1.2 ± 0.3 0.7 ± 0.1 <0.00001*
LVEF, % 62 ± 14 57 ± 17 0.11
LV Mass, g 166 ± 47 168 ± 57 0.87
No Myocardial Fibrosis, n (%) 13 (37.1) 23 (30.7) 0.82
Midwall Fibrosis, n (%) 11 (31.4) 27 (36.0) 0.82
Infarction Pattern Fibrosis, n (%) 11 (31.4) 25 (33.3) 0.82
LGE Mass 5.7 (7.6) 6.0 (7.9) 0.72
LGE Percent 3.4 (4.8) 3.8 (5.1) 0.71
Intervention
None 21 (60.0) 24 (32.0) 0.01*
AVR 9 (25.7) 25 (33.3) 0.01*
TAVR 5 (14.3) 26 (34.7) 0.01*
Table 1. Baseline Patient Data. Values are mean ± SD unless otherwise stated. *p < 0.05. Baseline data for 
AS patients based on severity. ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor 
blocker; AVR, aortic valve replacement; BMI, body mass index; CMR, cardiovascular magnetic resonance; DBP, 
diastolic blood pressure; LGE, late gadolinium enhancement; LVEF, left ventricular ejection fraction; NYHA, 
New York Heart Association; SBP, systolic blood pressure; TAVR, transcatheter aortic valve replacement.
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patients with mild/moderate disease and those with severe disease (62 ± 14% vs 57 ± 17%, p = 0.11). Per 10% change, 
LV ejection fraction did not have a significant effect on serum OPG (p = 0.77). On multivariable analysis (adjusted for 
age, sex, AS severity, and presence of myocardial fibrosis), there was still no effect observed (p = 0.39, Fig. 4).
NT-proBNP and Serum OPG Levels. NT-proBNP correlated with serum OPG levels in patients (rs = 0.30, 
p = 0.002; Table 2). A total of 64 (58.2%) patients met the diagnostic criteria for the heart failure with preserved 
ejection fraction (HFpEF) syndrome, characterised by heart failure symptoms, LV EF ≥ 50%, and a serum 
NT-proBNP > 125 pg/ml36. Serum OPG levels did not differ significantly between patients with HFpEF and those 
without (7.1 ± 3.6 pmol/L vs. 7.3 ± 3.5 pmol/L; p = 0.74). Patients with HFpEF were not more likely to have severe 
AS (p = 0.49), nor either pattern of fibrosis on CMR (p = 0.31).
Effect of OPG on survival. There were 30 (27.3%) deaths over the median follow-up period of 1.9 years 
(IQR 1.2–2.7 years). Using the Cox proportional hazards method, serum OPG had a significant effect on survival 
on univariable analysis (p < 0.0001). On multivariable analysis (adjusted for age, sex, AVR/TAVR intervention, 
presence of myocardial fibrosis, NYHA class, CAD, diabetes, and hypertension), this effect remained statistically 
significant, with every 1 pmol/L increase in baseline serum OPG increasing the risk of death by 19% (HR 1.19, 
95% CI 1.06–1.34; p = 0.004).
Variable
Spearman’s Correlation 
with OPG P-Value
Patient Demographics
Age, years 0.56 <0.0001*
Male, n (%) −0.025 0.80
Hypertension, n (%) −0.047 0.63
SBP, mmHg 0.015 0.88
DBP, mmHg −0.13 0.19
Diabetes mellitus, n (%) 0.024 0.82
Current smoker, n (%) 0.005 0.96
Any coronary artery disease, n (%) 0.10 0.29
Previous stroke, n (%) 0.0009 0.99
Atrial Fibrillation, n (%) −0.023 0.82
Hypercholesterolaemia, n (%) 0.028 0.78
NYHA ≥ II 0.033 0.73
Height, cm −0.17 0.077
Weight, kg −0.37 <0.0001*
BMI, kg/m2 −0.36 <0.001*
Pharmacotherapy
Aspirin, n (%) 0.006 0.95
Clopidogrel, n (%) 0.046 0.65
ACE-I/ARB, n (%) −0.11 0.26
Beta Blocker, n (%) −0.098 0.33
Calcium channel blocker, n (%) −0.25 0.014*
Diuretic, n (%) 0.25 0.009*
Warfarin, n (%) 0.061 0.55
Amiodarone, n (%) −0.071 0.48
Statin, n (%) −0.046 0.64
Biochemical Data
Creatinine, μmol/L 0.32 0.001*
NT-ProBNP (pg/mL) 0.30 0.002*
CRP (mg/L) 0.22 0.038*
CMR Data
CMR aortic valve area, cm2 −0.24 0.011*
LVEF, % −0.041 0.67
LV Mass, g −0.22 0.021*
LGE Mass 0.22 0.027*
LGE Percent 0.25 0.010*
Table 2. Correlations between Patient Data and Serum OPG levels. *p < 0.05. Correlation between Patient 
Data and Serum OPG Levels. ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor 
blocker; BMI, body mass index; CMR, cardiovascular magnetic resonance; DBP, diastolic blood pressure; LGE, 
late gadolinium enhancement; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; 
SBP, systolic blood pressure.
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Discussion
This is the first study to investigate the association between myocardial fibrosis on CMR and serum OPG levels 
in patients with AS. There was no association between midwall fibrosis and serum OPG levels in our study. 
However, for patients with chronic infarction pattern fibrosis on CMR, there was an effect on serum OPG on 
univariable analysis (p = 0.009), but there was only a trend on multivariable analysis when accounting for age, 
sex, AS severity, LVEF, NYHA, NT-proBNP, and CRP (p = 0.061). We included patients with both mild/moderate 
and severe AS, and confirmed the findings of others that disease severity is independently associated with raised 
serum OPG22–24. The patient groups were also well-matched in terms of baseline characteristics and medical 
therapy. Specifically, statin therapy, which reduces inflammatory (TNFα mediated) OPG release by endothelial 
cells37, did not differ between groups. While LVEF did not appear to have a significant effect on serum OPG in 
the current study, only 15 patients (13.6%) had a LVEF ≤ 40%, complicating the assessment of the effect of con-
comitant heart failure on OPG in our patient cohort. On multivariable analysis, the raised serum OPG in patients 
with chronic ischaemic pattern fibrosis on CMR appeared to associate more with older age and higher levels of 
serum NT-proBNP and CRP. Importantly, we have also confirmed the association between higher serum OPG 
and poorer mid-term survival (median 1.9 years in the present study) in patients with AS23, demonstrating a 19% 
increase in the risk of death per 1 pmol/L rise in serum in OPG. This is clinically important, as it appears that the 
risk associated with OPG elevation is independent of LVEF and midwall myocardial fibrosis.
In addition to regulating bone calcification38, the RANKL/RANK/OPG pathway also plays a key role in 
immune function via modulation of dendritic cell function, and is upregulated in T lymphocytes during inflam-
mation39. In addition to blockade of RANK, OPG also interacts with tumour necrosis factor related apoptosis 
inducing ligand (TRAIL), to block TRAIL-related apoptosis40. The RANKL/RANK/OPG axis is also active within 
the vasculature and has been shown to play a major role in pathological vascular calcification, in a manner anal-
ogous to bone turnover8, and is upregulated in accelerated atherosclerotic plaques16. OPG has been shown to 
Figure 1. Box and Whisker Plots of Osteoprotegerin levels by Aortic Stenosis Severity. Patients with severe 
disease had higher serum OPG levels than those with mild/moderate disease (7.91 ± 3.82 pmol/L vs 5.76 ± 1.96 
pmol/L, p = 0.002). Diamond represents the mean OPG level. Outlier data are included on the plots.
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Figure 2. Box and Whisker Plots of Osteoprotegerin levels by pattern of Myocardial Fibrosis on CMR. Patients 
with midwall fibrosis on CMR did not have significantly higher levels of OPG compared to those without 
fibrosis (median 6.78 pmol/L [IQR 4.64–8.61] vs median 5.25 pmol/L [IQR 4.26–7.95 pmol/L], p = 0.12). There 
was no difference between those with midwall or chronic infarction pattern fibrosis (median 6.78 pmol/L [IQR 
4.64–8.61 pmol/L] vs median 6.97 pmol/L [IQR 5.43–11.12 pmol/L], p = 0.27). However, OPG levels in patients 
with chronic infarction fibrosis were significantly higher than those without fibrosis (p = 0.005). Diamond 
represents the mean OPG level. Outlier data are included on the plots.
Figure 3. Effect of Extent of Fibrosis on OPG per %LGE on CMR. Panel (A) On multivariable linear regression 
analysis, ‘any’ fibrosis (per % increase in LGE on CMR) increased serum OPG by 0.16 pmol/L (95% CI 0.03–
0.30 pmol/L, p = 0.02). Panel (B) Separating out patients based on pattern of fibrosis, midwall fibrosis had no 
effect on OPG levels (0.10 pmol/L, 95% CI −0.13–0.32, p = 0.39), whereas chronic infarction pattern fibrosis 
increased serum OPG by 0.19 pmol/L (95% CI 0.03–0.35 pmol/L) for every 1% increase in LGE on CMR 
(p = 0.02).
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induce vascular fibrosis in aortic samples of apolipoprotein E knockout (ApoE[−/−]) mice, via transforming 
growth factor-β1 (TGF-β1), which also mediates OPG release in response to angiotensin II in vascular smooth 
muscle cells41. A recent meta-analysis including a total of 26,442 participants from the general population demon-
strated an association between raised baseline serum OPG and an increased risk of incident cardiovascular dis-
ease at a mean follow-up of 8.5 years, independent of age and clinically-relevant risk factors35.
Defining the role of OPG in patients with AS may therefore be complicated by the presence of concomitant 
cardiovascular disease. There also appears to be a difference between the actions of OPG in vascular and cardiac 
tissue in mouse models, as it has shown to be pro-fibrotic in the former41 and anti-fibrotic in the latter33. This 
may be explained by tissue-specific differences (e.g. in cellular autophagy), however, these effects are yet to be 
confirmed in humans. We have shown that severe AS is independently associated with raised serum OPG, and 
that patients with chronic ischaemia pattern fibrosis on CMR have raised OPG on univariate analysis. In patients 
with infarction, this is due to presence of coronary artery disease, but also due to a lower mean ejection fraction 
and higher serum CRP. In this way, LV dysfunction, systemic inflammation, and CAD are likely to mediate serum 
OPG in patients with infarction on CMR, in addition to the degree of calcification of the aortic valve. The effect 
of the severity of AS on serum OPG, as determined by aortic valve area on CMR, was shown to be independent 
of age, sex, fibrosis on CMR, LV EF, and NYHA. This suggests that progressive calcification of the valve itself is 
the cause of the raise in serum OPG. Of course, this is likely to be affected by progression to pressure overload 
induced heart failure, or potentially the presence of concomitant cardiovascular disease, such as CAD, HTN, 
diabetes, which can be associated with systemic inflammation and/or endothelial dysfunction16,42,43. Indeed, the 
severity of endothelial dysfunction in these conditions is heterogeneous and directly affected by medications such 
as Angiotensin II receptor blockers (ARB) and ACE-inhibitors44–46, which were used in 46.3% of patients in our 
cohort, but prescription rates were similar between severity groups. Serum OPG may present a further prognostic 
marker for patients with severe AS, and may aid in determining the ideal timing for surgical intervention, but 
does not predict the presence of midwall fibrosis on CMR.
Limitations. Our study was from a single centre and therefore subject referral bias, although we believe this 
was limited as our centre is a national referral centre with patients treated from across the country. In addition, 
our cohort contained predominantly Caucasian patients and therefore our results cannot be extrapolated to other 
ethnicities. Finally, we did not undertake T1-mapping with the CMR scanning, as it had not been validated in 
our institution at the time of recruiting our patients, and therefore we are unable to comment about the potential 
association between OPG and interstitial/diffuse fibrosis. Nonetheless, it is important to emphasise the predictive 
role of OPG in this cohort.
Conclusion
There was no association between serum OPG and the presence of myocardial midwall fibrosis in our study. 
However, higher OPG levels were seen in patients with chronic myocardial infarction compared to patients with 
no fibrosis, which was due to increased levels of serum markers of inflammation, LV dysfunction, and CAD. We 
have confirmed the findings of others that OPG levels increase with AS severity, and that increased serum OPG 
levels are associated with poorer survival at mid-term follow-up (median of 1.9 years), independent of the pres-
ence of midwall fibrosis on the CMR. These data suggest that the RANKL/RANK/OPG axis is unlikely to play a 
central role in myocardial midwall fibrosis in patients with aortic stenosis.
Data Availability
Data can be obtained from the corresponding author and will be deposited in an open access repository upon 
acceptance.
Figure 4. Effect of EF on OPG Levels. On multivariable linear regression analysis (adjusted for age, sex, AS 
severity, and presence of myocardial fibrosis), serum OPG levels remained unchanged per 10% change in LV 
ejection fraction (0.18 pmol/L, 95% CI −0.23–0.59 pmol/L, p = 0.39).
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